Know Cancer

forgot password

Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features

Phase 1
18 Years
Open (Enrolling)
Carcinoid, Neuroendocrine

Thank you

Trial Information

Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features

This is the first study in man of Seneca Valley Virus, a virus which seeks and kills certain
tumors in non-human model systems. Subjects in this trial will be patients with advanced
cancer displaying certain specified neuroendocrine features, pathologically; they will have
exhausted standard methods of treatment for their tumor. The primary purpose of the trial is
to determine if the virus may be administered safely. Additional purposes are to learn
about the distribution of the virus in the body, the elimination of the virus from the body,
the immune response to the virus and whether the virus might have some beneficial effects
upon the tumors which the patients have. The first patients will be treated with low amounts
of virus and subsequent patients may receive higher amounts. At the end of the trial, it is
intended to select a dose for further study.

Inclusion Criteria:

- Patients must have a histologically confirmed solid tumor (including carcinoid) with
neuroendocrine features (i.e., expression of >= 1 of the following 3 markers:
synaptophysin, chromogranin A, or CD56) that is metastatic or unresectable and for
which standard curative or palliative measures do not exist or are no longer

- Patients must show evidence of disease progression in the three months prior to
treatment with SVV-001.

- Age >= 18 years. Because no dosing or adverse event data are currently available on
the use of SVV-001 in patients <18 years of age, children are excluded from this
study. Children may be eligible for future pediatric Phase I single-agent trials.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

- Life expectancy >= 24 weeks.

- Adequate bone marrow, hepatic, and renal function as defined below:

- absolute lymphocyte count >= 1,000/ul

- absolute neutrophil count >= 1,500/ul

- platelets >= 100,000/ul

- AST/ALT <= 2.5 x upper limit of normal (ULN) or <= 5 x ULN if liver metastases

- total bilirubin <= 1.5 x upper limit of normal

- creatinine <= 1.5 x upper limit of normal OR

- creatinine clearance (calculated) <= 60 mL/min/1.73 m2 for patients with
creatinine > 1.5 x upper limit of normal.

- Women must have been surgically sterilized or be post-menopausal.

- Men must agree to use adequate contraception (barrier method of birth control;
abstinence) prior to study entry and for up to 6 months.

- Ability to understand and the willingness to sign a written informed consent

- Patients must have oxygen saturation of at least 95% on room air.

- Patients must have measurable disease by RECIST (CT and/or MRI).

Exclusion Criteria:

- Patients with small cell histology.

- Patients who have been hospitalized for emergent conditions requiring inpatient
evaluation, treatment or procedure during the 30 days prior to entry on study. In
addition, emergent conditions requiring inpatient evaluation, treatment or procedure
must have resolved or be medically stable and not severe for 30 days prior to entry
on study.

- Use of chemotherapy or radiotherapy within 4 weeks of initiation of SVV-001, or
continued > Grade 1 adverse events, excluding alopecia, due to agents administered
more than 4 weeks earlier.

- Patients with clinically evident Human Immuno-deficiency Virus (HIV), Hepatitis B
Virus (HBV) or Hepatitis C Virus (HCV) infection.

- Patients with > Grade 1 peripheral neuropathy (CTCAE version 3.0).

- Concurrent use of any other investigational agents.

- Presence of or history of central nervous system metastasis.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pre-menopausal women who have not been surgically sterilized. Although SVV-001 has no
affect on the ovaries from a toxicological perspective, SVV-001 RNA is present in the
ovaries at 12 weeks in animals that were administered high and medium doses. No
pre-clinical reproductive tests have been conducted with SVV-001.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence of dose-limiting toxicity and determination of phase II dose

Outcome Time Frame:

Within 28 days of treatment administration

Safety Issue:


Principal Investigator

Rudin Charles, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Sidney Kimmel Comprehensive Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

April 2006

Completion Date:

December 2008

Related Keywords:

  • Carcinoid
  • Neuroendocrine
  • advanced carcinoma
  • carcinoid
  • neuroendocrine features
  • oncolytic virus
  • phase I study
  • dose escalation study
  • rhabdomyosarcoma
  • alveolar rhabdomyosarcoma
  • medulloblastoma
  • rhabdoid
  • glioblastoma
  • ewing's sarcoma
  • pediatric oncologies
  • neuroblastoma
  • wilms' tumor
  • retinoblastoma
  • Large cell lung cancer
  • Carcinoid Tumor



Virginia Oncology Associates Newport News, Virginia  23606
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Tyler Cancer Center Tyler, Texas  75702
Cancer Centers of Florida Orlando, Florida  32806
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231
Central Indiana Cancer Centers Indianapolis, Indiana  46227
Mary Crowley Research Center Dallas, Texas  75246
New York Oncology Hematology P.C. Albany, New York  12208
Dayton Oncology & Hematology, P.A . Kettering, Ohio  45409
Northwest Cancer Specialists - Vancouver Cancer Center Vancouver, Washington  98684